Delphia Therapeutics website screenshot

Delphia Therapeutics

Delphia Therapeutics is a Cambridge, Massachusetts oncology biotechnology company pioneering "activation lethality," a precision-medicine approach that targets cancer cells' vulnerability to oncogene overactivation by selectively over-activating cancer-linked signaling until tumor cells can no longer survive. Founded by oncology drug developers Kevin Marks, Bill Sellers, and Mike Dillon, the company launched with a $67 million Series A financing led by GV, with participation from Nextech Invest, Polaris Innovation Fund, and Alexandria Venture Investments. Delphia is a preclinical-stage drug developer and does not currently publish a public developer API, SDK, or developer portal.

Delphia Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Oncology, Biotechnology, and Cancer.

Delphia Therapeutics’ developer surface includes engineering blog and 3 more developer resources.

🌐 Visit website 📡 Source on GitHub
11.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyLife SciencesOncologyBiotechnologyCancerPrecision MedicinePharmaceuticals

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 11.2/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.4 / 20
Commercial Clarity 2.1 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/delphia-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Delphia Therapeutics Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy

Company 2

The organization behind the API

Website
Website
 Blog
Blog

Source (apis.yml)

apis.yml Raw ↑ 
aid: delphia-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/delphia-therapeutics.png
name: Delphia Therapeutics
description: Delphia Therapeutics is a Cambridge, Massachusetts oncology biotechnology company pioneering "activation lethality,"
  a precision-medicine approach that targets cancer cells' vulnerability to oncogene overactivation by selectively over-activating
  cancer-linked signaling until tumor cells can no longer survive. Founded by oncology drug developers Kevin Marks, Bill Sellers,
  and Mike Dillon, the company launched with a $67 million Series A financing led by GV, with participation from Nextech Invest,
  Polaris Innovation Fund, and Alexandria Venture Investments. Delphia is a preclinical-stage drug developer and does not
  currently publish a public developer API, SDK, or developer portal.
url: https://raw.githubusercontent.com/api-evangelist/delphia-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Life Sciences
- Oncology
- Biotechnology
- Cancer
- Precision Medicine
- Pharmaceuticals
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/delphia-therapeutics-domain-security.yml
- type: Website
  url: https://www.delphiatx.com
- type: PrivacyPolicy
  url: https://www.delphiatx.com/privacy-policy/
- type: Blog
  url: https://www.delphiatx.com/news/
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence